Upgrade to SI Premium - Free Trial

Immuneering Corporation (IMRX)

4.47 +0.01 (0.22%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/12/26)

Latest Headlines

Immuneering publishes preclinical data on atebimetinib in Cancer Research July 21, 2026 4:06 PM - StreetInsider Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition July 21, 2026 4:05 PM - StreetInsider Form 4 Immuneering Corp For: Jul 16 Filed by: Gengos Andrew July 17, 2026 4:29 PM - SEC Filing Immuneering Corporation Announces Grants of Inducement Awards July 17, 2026 4:05 PM - StreetInsider Form 3 Immuneering Corp For: Jul 16 Filed by: Gengos Andrew July 16, 2026 4:11 PM - SEC Filing Immuneering Corporation (IMRX) 7500 contracts of August 75 calls as share price up 6.2% July 8, 2026 2:34 PM - StreetInsider Cantor Fitzgerald Starts Immuneering Corporation (IMRX) at Overweight July 8, 2026 6:06 AM - StreetInsider Kalaris Therapeutics names Laurie Keating to its board July 6, 2026 4:05 PM - StreetInsider Form 4 Immuneering Corp For: Jun 23 Filed by: Zeskind Benjamin J. June 24, 2026 4:11 PM - SEC Filing Form 4 Immuneering Corp For: Jun 15 Filed by: Hall Brett Matthew June 16, 2026 4:15 PM - SEC Filing Form 8-K Immuneering Corp For: Jun 11 June 15, 2026 4:12 PM - SEC Filing Immuneering names Andrew Gengos as chief financial officer June 15, 2026 7:30 AM - StreetInsider Immuneering Appoints Andrew Gengos as Chief Financial Officer June 15, 2026 7:30 AM - StreetInsider Form 4 Immuneering Corp For: Jun 11 Filed by: Schall Thomas J. June 11, 2026 5:38 PM - SEC Filing Form 4 Immuneering Corp For: Jun 11 Filed by: HAUSMAN DIANA June 11, 2026 5:33 PM - SEC Filing Form 4 Immuneering Corp For: Jun 11 Filed by: CARPENTER ROBERT J June 11, 2026 5:30 PM - SEC Filing Form 4 Immuneering Corp For: Jun 11 Filed by: KEATING LAURIE June 11, 2026 5:26 PM - SEC Filing Form 4 Immuneering Corp For: Jun 11 Filed by: Feinberg Peter June 11, 2026 5:23 PM - SEC Filing Form 8-K Immuneering Corp For: Jun 11 June 11, 2026 5:16 PM - SEC Filing Immuneering doses first patient in phase 3 pancreatic cancer trial June 11, 2026 7:30 AM - StreetInsider Immuneering doses first patient in phase 3 pancreatic cancer trial June 11, 2026 7:30 AM - StreetInsider Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer June 11, 2026 7:30 AM - Globe NewsWire Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer June 11, 2026 7:30 AM - StreetInsider Mizuho defends Immuneering Corporation (IMRX), 'recommend being opportunistic on IMRX' June 2, 2026 6:43 AM - StreetInsider Form 8-K Immuneering Corp For: Jun 01 June 1, 2026 4:52 PM - SEC Filing Oppenheimer Reiterates Outperform Rating on Immuneering Corporation (IMRX) Following Data June 1, 2026 9:59 AM - StreetInsider Immuneering reports 17.3-month survival data for pancreatic cancer drug June 1, 2026 7:31 AM - StreetInsider Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO June 1, 2026 7:30 AM - StreetInsider Immuneering reports 17.3-month survival in pancreatic cancer trial May 21, 2026 5:02 PM - StreetInsider Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy May 21, 2026 5:00 PM - Globe NewsWire Form 10-Q Immuneering Corp For: Mar 31 May 15, 2026 7:52 AM - SEC Filing Form 8-K Immuneering Corp For: May 15 May 15, 2026 7:44 AM - SEC Filing Immuneering reports Q1 2026 financial results and clinical updates May 15, 2026 7:35 AM - StreetInsider Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates May 15, 2026 7:35 AM - Globe NewsWire Full Article List